Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$97.21M

FY 2025 · Annual

Investing Cash Flow

-$102,000.00

FY 2025 · Annual

Financing Cash Flow

$70.75M

FY 2025 · Annual

+149.3% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(178.3M)(192.28M)(257.83M)(97.94M)(122.93M)
Depreciation & Amortization17.64M20.56M22.19M9.36M7.6M
Deferred Income Tax2.77M0(6.34M)00
Stock-Based Compensation32.96M31.65M27.36M12.38M9.08M
Change in Working Capital(101.9M)(82.32M)(164.03M)4.51M(4.22M)
Accounts Receivables(789K)2.34M(976K)953K155K
Inventory7.66M0000
Accounts Payables(7.66M)13.35M5.59M(14.17M)2.79M
Other Working Capital(101.11M)(98M)(168.65M)17.72M(7.17M)
Other Non-Cash Items(6.43M)(1.24M)153.8M4.55M13.27M
Operating Cash Flow(233.25M)(223.63M)(224.84M)(67.14M)(97.21M)
Capital Expenditures(23.28M)(20.17M)(21.16M)(267K)(102K)
Acquisitions (Net)(119K)(79.46M)01.95M0
Purchases of Investments(338.16M)(277.39M)(59.55M)00
Sales of Investments609.76M356.85M234.24M35.84M0
Other Investing Activities079.46M000
Investing Cash Flow248.2M59.29M153.53M37.52M(102K)
Debt Repayment00000
Common Stock Issued27.1M84.87M15.11M28.99M74.01M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.76M(209K)(518K)(614K)(3.26M)
Financing Cash Flow32.86M84.66M14.59M28.38M70.75M
Effect of Forex Changes(263K)1.25M1.48M(2.05M)4.09M
Net Change in Cash47.54M(78.43M)(55.24M)(3.29M)(22.47M)
Free Cash Flow(256.53M)(243.8M)(246M)(67.41M)(97.31M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$122.9M
+ D&A$7.6M
+ Stock-Based Comp$9.1M
+ Deferred Tax$0
- Working Capital-$4.2M
+ Other Non-Cash$13.3M
= Operating Cash Flow-$97.2M
- Capex-$102.0K
= Free Cash Flow-$97.3M

Analysis

FY2025 free cash flow is -$97.3M. FCF conversion is 79.2% of net income. Operating cash flow was -$97.2M, with capex of -$102.0K. The largest bridge item is Other Non-Cash at $13.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipMay 27, 2026
4Statement of changes in beneficial ownershipMay 27, 2026
4Statement of changes in beneficial ownershipMay 27, 2026
4Statement of changes in beneficial ownershipMay 27, 2026
4Statement of changes in beneficial ownershipMay 27, 2026

Does SGMO generate free cash flow?

Sangamo Therapeutics, Inc. (SGMO) generated -$97.31M of free cash flow in fiscal 2025.

How much operating cash flow does SGMO produce?

Operating cash flow was -$97.21M, before capital expenditures of $102,000.00.